Kiyoshi
Kakuta
,
Ryouta
Kasahara
,
Kazuki
Sato
and
Takeshi
Wada
*
Department of Medicinal and Life Sciences, Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan. E-mail: twada@rs.tus.ac.jp; kazuki_sato@rs.tus.ac.jp
First published on 1st September 2023
In this study, we developed a new approach for the solid-phase synthesis of oligodeoxynucleotides (ODNs) using nucleobase-unprotected oxazaphospholidine derivatives. We tackled the problem of the difficult purification of N-unprotected monomers due to their high affinity to silica gel by introducing a tetrahydrogeranyl group into the oxazaphospholidine monomers, thereby enhancing the lipophilicity and facilitating the isolation. In addition, the cyclic structure of oxazaphospholidine enabled a hydroxy-group-selective condensation with sufficient efficiency. Unmodified and boranophosphate/phosphate chimeric ODNs were successfully synthesized using this strategy. This synthetic method can be expected to afford ODNs containing base-labile functional groups.
Hayakawa et al. reported the synthesis of oligonucleotides using nucleobase-unprotected phosphoramidite derivatives.6,7 They found that using imidazolium triflate as an acidic activator can reduce the nucleobase phosphitylation to some extent. However, a part of the amino groups is still phosphitylated during the condensation reaction, and treatment with benzimidazolium triflate–methanol to cleave the P–N bond(s) is necessary after each condensation.6,7 An improved version of the nucleobase-unprotected approach was the proton-block method reported by Sekine et al.8 In this method, the amino groups of nucleobases are temporary protected as unreactive protonated forms during condensation to prevent the reaction with an activated monomer using an acidic activator having relatively low pKa values, affording 20-mer ODNs.
Meanwhile, we previously reported that the condensation reaction using nucleobase-unprotected oxazaphospholidine derivatives proceeded with a hydroxy group in a chemoselective manner even under mild acidic conditions.9–11 Oxazaphospholidines are cyclic phosphoramidite derivatives that were originally developed to synthesize P-stereodefined oligonucleotides.12 The chemoselectivity brought by the oxazaphospholidine derivatives can be explained in terms of an intramolecular recyclization that regenerates the oxazaphospholidine derivatives and the nucleobase having a free amino9,10 or imide11 group (Scheme 1).
In such reports, we synthesized 5-H/N-Me- and 5-Ph/N-Me-substituted oxazaphospholidine derivatives with unprotected nucleobases (Scheme 2) and obtained unmodified ODNs up to tetramers and boranophosphate (PB) DNAs up to dimers using the former and the latter monomers, respectively. PB DNAs, in which one of the nonbridging oxygen atoms of the phosphodiester is substituted with a borano group (BH3), have attractive properties as antisense oligonucleotides, such as high nuclease resistance and lipophilicity and low cytotoxicity.13,14 When acyl-type amino protecting groups, which are widely used for nucleobase protection, are employed for the synthesis of PB DNAs, irreversible reduction of amide groups to alkylamino groups occurs as a serious side reaction during the boronation reaction.15 This problem can be overcome by using synthetic strategies without nucleobase protection.9,16 However, when using 5-H/N-Me- or 5-Ph/N-Me-substituted monomers, the synthesis of longer oligomers was unsuccessful, which was attributed to insufficient condensation efficiency, especially in the case of the deoxyguanosine monomer. Moreover, the purity of the isolated unprotected deoxyguanosine monomer was not satisfactory (ca. 81% for the 5-H/N-Me-substituted derivative and ca. 71% for the 5-Ph/N-Me-substituted derivative according to a 31P NMR spectroscopic analysis), most likely due to the high affinity of the monomer to silica gel, which results in a longer elution and, consequently, in the decomposition of the monomer.
To address this issue, in this study, we introduced a long alkyl chain into the oxazaphospholidine monomer to endow it with lipophilicity. The tetrahydrogeranyl (Thg) group, which has a branched structure, was selected as the long alkyl group because it would also improve the monomer solubility in reaction solvents compared with linear alkyl groups due to diminished interactions between branched alkyl chains.17 Herein, we demonstrate that the monomers were applicable to the synthesis of ODNs up to dodecamers and oligonucleotides contain PB linkages.
Next, the synthesis of oxazaphospholidine monomers with a iPr or Thg group introduced into the N-atom of the oxazaphospholidine ring was carried out. These monomer units were synthesized using unprotected nucleosides including deoxyribose and 2′-O-4′-C-locked nucleoside (LNA)20 derivatives and phosphitylating reagents 4i (R = iPr) or 4t (R = Thg), which was prepared from phosphorus trichloride and amino alcohols 3i (R = iPr) or 3t (R = Thg). The compounds 4 were not isolated considering the chemical instability and used after only removal of insoluble salts by filtration in the following reaction. For the synthesis of the deoxyadenosine and deoxycytidine derivatives, the reactions were conducted at −78 °C to prevent the phosphitylation of the unprotected amino groups. In the case of the deoxyguanosine derivative, the reaction was performed at −40 °C to enhance the conversion rate. Meanwhile, the phosphitylation of the thymidine and LNA thymidine derivatives was conducted initially at −78 °C and finally at room temperature (rt) through gradual warming. The deoxyadenosine, deoxycytidine, thymidine, and LNA thymidine oxazaphospholidine monomers were isolated with high purity and moderate yields (6i, 27%; 6a, 34%; 6c, 39%; 6t, 55%; 6l, 32%) via silica gel column chromatography. It is worth noting that t-butyl alcohol was effective as the eluent of silica gel chromatography in the case of the deoxycytidine and deoxyguanosine derivatives. When methanol was used as an eluent, the purified oxazaphospholidine monomer decomposed to phosphitetriester during the solvent removal process. Thus, an alcohol with low nucleophilicity was more suitable as a polar eluent. In the case of the deoxyguanosine monomer, the purity was about 90% (determined via31P NMR spectroscopy) and its separation from oxidized compounds via silica gel column chromatography was troublesome. Therefore, reversed-phase high-performance liquid chromatography (RP-HPLC) was used to purify the monomer after a silica gel column chromatography which roughly removed highly polar compounds and reduced the burden on HPLC columns. As a result, the deoxyguanosine monomer was isolated with a high purity and moderate yield (6g, 30%).
Although the isolated yields of N-Thg monomers were in the range of 30%–55%, these yields were considerably higher than those of 5-Ph/N-Me-substituted unprotected monomers, especially deoxycytidine and deoxyguanosine derivatives (17% and 3%, respectively). In addition to this, the isolated yield of N-Thg monomer was higher than that of N-iPr-substituted monomer (6i; 27% vs.6c; 39%). TLC monitoring of the reaction mixtures indicated that the conversion rates of 5c and 5g to 6c and 6g were about 50%, which were low compared with those of their N-Me-substituted counterparts probably due to the steric hindrance of the alkyl group. However, the higher isolation yields of the N-Thg derivatives compared with those of the N-Me derivatives can be attributed to their easier purification and higher chemical stability. Although a greater excess of compound 4t could lead to the completion of the reaction, no optimization of equivalents of phosphitylating reagent was conducted.
To begin with, the condensation efficiency was compared using N-Me-, N-iPr-, and N-Thg-substituted monomers. The HPLC yields of dinucleotide phosphates other than the deoxyguanosine derivative were 95%–97% when the N-Me-substituted monomers were used, whereas N-iPr- and N-Thg-substituted monomers afforded the corresponding products in HPLC yields higher than 99% (Table 1, entries 1–3 vs. 4–7), as confirmed by the area ratio defined by product/(product + Th). This result suggested that the N-iPr- and N-Thg-substituted monomers exhibited higher coupling efficiencies. In general, the phosphoramidite reactivity is known to be largely affected by steric hindrance.25 However, in this case, the steric hindrance of the N-Me-substituted monomers around the N-atom are small, resulting in immediate hydrolysis during condensation. Thus, the introduction of the iPr and Thg groups improved the stability of the monomer while maintaining satisfactory condensation efficiency. The N-Thg-substituted monomer was chosen as an optimal monomer unit due to the higher isolated yield of the monomer.
Entry | Producta | R | Yieldb (%) |
---|---|---|---|
a Subscript PO = phosphate, superscript L = LNA. b Determined via RP-HPLC. c Isolated yield, determined according to the UV absorbance at 260 nm. | |||
1 | dCPOT 10c | Me | 97 |
2 | dAPOT 10a | Me | 95 |
3 | TPOT 10t | Me | 97 |
4 | dCPOT 10c | iPr | >99 |
5 | dCPOT 10c | Thg | >99 |
6 | dAPOT 10a | Thg | >99 |
7 | TPOT 10t | Thg | >99 |
8 | dGPOT 10g | Thg | >99 |
9 | LTPOT 10l | Thg | >99 |
10 | d(CPOAPOGPOTPOCPOAPOGPOTPOCPOAPOGPOT) (11) | Thg | 14c |
Then, the deoxyguanosine monomer was examined for the synthesis of dimers (Table 1, entry 7). The dGPOT dimer was obtained in more than 99% HPLC yield. No phosphitylation on the nucleobase amino groups was observed using oxazaphospholidine monomers bearing the N-Thg group. In addition, the synthesis was performed using LNA thymidine monomer 6l, obtaining the LTPOT dimer (the superscript L indicates LNA nucleoside) in more than 99% HPLC yield. The LNA monomer also exhibited high condensation efficiency, although the reactivity of LNA derivatives is typically low due to the steric hindrance caused by the 2′ and 4′ locked structure.
Next, the synthesis of a dodecamer of deoxyribonucleotide d(CPOAPOGPOTPOCPOAPOGPOTPOCPOAPOGPOT) 11 bearing four nucleobases was investigated. Fig. S2† shows the UPLC profile of crude 11, which indicates that the desired product was obtained as the main product. The dodecamer was isolated in 14% yield, identified via mass spectrometry, and analyzed using 1H and 31P NMR spectroscopies (Fig. S7 and S8†). The 1H NMR spectrum revealed the presence of signals stemming from the sugar backbone and the nucleobases. Meanwhile, in the 31P NMR spectrum, only signals in the PO region were observed (Fig. S8†).
Finally, the purity of the synthesized oligomer was compared with that of a commercial one via RP-UPLC. The peaks of both products appeared at the same retention time, confirming the successful synthesis of the oligomer with similar purity to that of the commercial product and demonstrating that the newly designed monomers enable the synthesis of a PO ODN without nucleobase protection.
First, the dinucleoside boranophosphate was synthesized using the deoxycytidine monomer under boronation conditions with 1.0 M BH3·SMe2/toluene. The HPLC yield of the target compound was 97% as confirmed by the product/product + Th area ratios. This result prompted us to synthesize the trinucleoside boranophosphate. Since our group found that the boronation reagent and/or its residue(s) inhibited the subsequent condensation reaction in the synthesis of tetrasaccharide boranophosphate,31 a washing step with EtOH was conducted after the boronation reaction to remove the reagent. However, the coupling yield of the second condensation reaction was not satisfactory; specifically, dCPBT and d(CPBCPBT) were obtained in 12% and 85% HPLC yields, respectively (Table 2, entry 2). To address this issue, the boronation conditions were investigated, finding that boronation using 0.05 M BH3·THF/THF for 2 min were the optimal conditions (see ESI† for details), which provided dCPBT in a comparable yield to that obtained when using harsher conditions. With regard to the synthesis of trimers, the HPLC yield of d(CPBCPBT) was improved to 94%.
Entry | Producta | Boronation conditions | T![]() ![]() ![]() ![]() ![]() ![]() |
---|---|---|---|
a Subscript PB = boranophosphate. b Determined via RP-HPLC. c Ammonia treatment was conducted at rt, for 3 h and then at 50 °C for 17 h. | |||
1 | dCPBT 14c | 1.0 M BH3·SMe2/toluene | 3![]() ![]() |
2 | d(CPBCPBT) 15 | 1.0 M BH3·SMe2/toluene | 3![]() ![]() ![]() ![]() |
3 | dCPBT 14c | 0.05 M BH3·THF/THF | 3![]() ![]() |
4 | d(CPBCPBT) 15 | 0.05M BH3·THF/THF | 1![]() ![]() ![]() ![]() |
5 | dAPBT 14ac | 0.05 M BH3·THF/THF | 1![]() ![]() |
6 | dGPBT 14g | 0.05 M BH3·THF/THF | 1![]() ![]() |
7 | TPBT 14t | 0.05 M BH3·THF/THF | 2![]() ![]() |
When other nucleobase monomers were used for the synthesis of dimers, the dAPBT, dGPBT, and TPBT dimers were obtained in 97%–99% HPLC yields (Table 2, entries 5–7). In the case of dAPBT, the removal of the borane adducts on the N1 and/or N7 positions of an adenine29 required ammonia treatment for longer time and higher temperature, whereas other nucleobases did not require high-temperature conditions.32 As summarized in Table 2, the dinucleoside and trinucleoside boranophosphates were synthesized in satisfactory HPLC yields without considerable amounts of byproducts.
Fig. S5† shows the HPLC profiles of all-PB and PB/PO chimeric tetramers, i.e., d(CPBAPBGPBT) 16 and d(CPBAPOGPBT) 17, respectively, which indicate that the desired products were obtained as the main products. Tetramers 16 and 17 were isolated in 28% and 33% yields, respectively (Table 3, entries 1 and 2). The isolated compounds were analyzed via1H NMR spectroscopy. The corresponding NMR spectra showed the characteristic signals of nucleobases and the borano groups (Fig. S9 and S10†). The successful synthesis of the PB/PO chimeric tetramer indicated that the PB linkages were stable under the oxidation conditions using TBHP.
In a similar manner, PB/PO chimeric dodecamer 18 containing alternate PB moieties was synthesized. Considering the number of protecting groups on the PO and PB moieties, a longer DBU treatment was performed.27,28 After RP-HPLC purification, dodecamer 18 was obtained in a 3% yield (Table 3, entry 3). The oligomer was identified via mass spectrometry. Peaks corresponding to deboronated and nucleotide deletion compounds were not detected. Unfortunately, the low yield of 18, which can be attributed to the inferior coupling efficiency after boronation, prevented us from recording a 1H NMR spectrum. Nevertheless, although there is room for improvement, the synthesis of chimeric oligonucleotides was achieved.
This synthetic strategy could be also applicable to the synthesis of stereocontrolled PB ODNs because the oxazaphospholidine method was originally developed to synthesize stereopure P-modified oligonucleotides. Further investigation on the synthesis of stereopure oligonucleotides containing PB, PS, and PO linkages based on this concept is now in progress.
The RP-HPLC analysis was performed at 260 nm, 30 °C, and a flow rate of 0.5 mL min−1 using a C18 column (100 Å, 3.9 mm × 150 mm) unless otherwise noted. The RP-UPLC measurements were performed at 260 nm, 50 °C, and a flow rate of 0.5 mL min−1 using a C18 column 1.7 μm (2.1 mm × 50 mm) unless otherwise noted.
The amount of a loaded nucleoside on solid-support was estimated by the calculation of released 4,4′-dimethoxytrityl cation by a solution of 0.1 M TsOH/CH3CN using a molar absorption constant at 498 nm (ε = 76000 L mol−1 cm−1).33
The isolated yields of the synthesized oligomers were estimated via UV–vis spectroscopy. The PB/PO chimeric dodecamer was only characterized via ESI MS owing to the small quantities obtained. The isolation of the oxazaphospholidine monomer via RP-HPLC was conducted with detection at 260 nm, at rt, and a flow rate of 10 mL min−1 using a C18 column (120 Å) unless otherwise noted.
The crude products were dissolved in dry THF (260 mL), and tetrahydrogeraniol (22.3 mL, 116 mmol) and PPh3 (44.0 g, 168 mmol) were then added. To this solution, a diisopropyl azodicarboxylate solution in dry THF (33.0 mL, 168 mmol per 150 mL) was added at 0 °C, and the mixture was then warmed to rt. After 24 h, the reaction was quenched by adding MeOH (7 mL) and concentrated under reduced pressure. A mixed solution of hexane–EtOAc (6:
1, v/v 350 mL) was added to the residue and then cooled at 0 °C. Triphenyl phosphine oxide was removed by means of repeated precipitation, filtration, evaporation, dilution, and cooling. These operations were conducted three times. EtOAc (500 mL) was added to the residue, and the organic layer was washed with saturated aqueous solutions of NaCl (3 × 200 mL). The aqueous layers were combined and extracted with EtOAc (2 × 200 mL), and the combined organic layers were dried over Na2SO4, filtered, and concentrated to give a light-yellow oil.
MeOH (41.5 mL) and a 3% TFA/CH2Cl2 solution (360 mL) were added to the crude product at rt. After 18 h, the mixture was washed with saturated aqueous solutions of NaHCO3 (3 × 200 mL). The aqueous layers were combined and extracted with CH2Cl2 (2 × 200 mL). The organic layers were combined and dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude product was purified via silica gel column chromatography (neutral silica gel) using CHCl3–hexane (5:
5–10
:
0, v/v) as an eluent to afford 2 as light yellow oil (32.4 g, 70 mmol, 85% from 1).
1H NMR (400 MHz, CDCl3) δ 8.05–8.02 (m, 1H, Ar), 7.72–7.60 (m, 3H, Ar), 7.36–7.26 (m, 5H, Ar), 4.90 (dt, J = 8.5, 3.5 Hz, 1H, Ph–C), 3.56–3.29 (m, 4H, H-2, NC
2), 2.77–2.75 (m, 1H, O
, mixtures of diastereomers), 1.60–1.03 (m, 10H, C
2 × 4, C
× 2), 0.90–0.81 (m, 9H, C
3 × 3). 13C {1H} NMR (101 MHz, CDCl3) δ 148.0, 141.1, 141.1, 133.6, 133.2, 131.6, 130.9, 128.6, 128.1, 125.8, 124.2, 79.0, 72.5, 72.3, 54.8, 54.7, 47.2, 47.0, 39.1, 36.9, 36.9, 34.8, 34.7, 30.6, 30.5, 28.0, 27.9, 24.5, 22.6, 22.5, 19.4, 19.3.
HRMS (ESI-QTOF) m/z: [M + H]+ calcd for C24H35N2O5S+, 463.2262; found 463.2262.
1H NMR (400 MHz, CDCl3) δ 7.39–7.25 (m, 5H, Ar), 4.75 (dd, J = 9.1, 3.7 Hz, 1H, H-1), 2.93 (dt, J = 11.9, 3.2 Hz, 1H, H-2), 2.78–2.60 (m, 3H, H-2, NC2), 2.6–2.1 (br, 2H, O
, N
), 1.58–1.45 (m, 3H, C
2 × 0.5, C
× 2), 1.37–1.19 (m, 4H, C
2 × 2), 1.18–1.05 (m, 3H, C
2 × 1.5), 0.87 (m, 9H, C
3 × 3). 13C {1H} NMR (101 MHz, CDCl3) δ 142.5, 128.4, 127.5, 125.8, 71.4, 71.4, 57.1, 57.0, 47.4, 47.3, 39.2, 37.3, 37.2, 30.8, 28.0, 24.7, 22.7, 22.6, 19.7.
HRMS (ESI-QTOF) m/z: [M + H]+ calcd for C18H32NO+, 278.2479; found 278.2474.
Seven tenths of the crude product (2.75 g out of 3.92 g) obtained in the synthesis of 6a was purified via silica gel column chromatography (NH-silica gel) using toluene–EtOAc (10:
0–8
:
2, v/v, containing 0.5% triethylamine) as an eluent to afford 6a as a colorless foam (0.82 g, 0.95 mmol, 34%).
1H NMR (400 MHz, CDCl3) δ 8.31, 8.30 (s, s, 1H, H-2, diastereomers), 7.99 (s, 1H, H-8), 7.41–7.16 (m, 14H, Ar), 6.80–6.74 (m, 4H, Ar), 6.48–6.44 (m, 1H, H-1′), 5.67 (brs, 2H, N2), 5.59–5.54 (m, 1H, 5-position of oxazaphospholidine), 5.01 (qd, J = 5.8, 2.9 Hz, 1H, H-3′), 4.23 (q, J = 3.4 Hz, 1H, H-4′), 3.77, 3.77, 3.74 (s, s, s, 6H, OC
3 × 2, diastereomers), 3.58–3.34 (m, 3H, H-5′, 5′′, 4-position of oxazaphospholidine), 3.09–2.97 (m, 2H, NC
2), 2.95–2.85 (m, 2H, 4-position of oxazaphospholidine, H-2′), 2.61–2.54 (m, 1H, H-2′′), 1.62–1.04 (m, 10H, C
2 × 4, C
× 2), 0.88–0.82 (m, 9H, C
3 × 3). 13C {1H} NMR (101 MHz, CDCl3) δ 158.5, 158.5, 155.4, 153.0, 149.7, 149.7, 144.5, 144.5, 140.5, 139.0, 135.7, 130.0, 128.5, 128.2, 128.0, 127.8, 127.8, 126.9, 126.8, 125.8, 125.8, 120.1, 113.1, 86.5, 86.0 (d, 3JPC = 4.8 Hz), 85.8, 84.3, 81.5, 81.4, 81.2, 72.9 (d, 2JPC = 10.6 Hz), 72.8 (d, 2JPC = 9.6 Hz), 63.3, 54.5 (d, 2JPC = 4.8 Hz), 43.7 (d, 2JPC = 22.2 Hz), 43.3 (d, 2JPC = 21.2 Hz) 40.1, 39.8, 39.2, 37.3, 37.1, 37.0, 36.8, 36.7, 36.7, 36.6, 36.4, 36.4, 30.5, 30.5, 30.4, 27.9, 24.7, 22.7, 22.6, 19.6, 19.5, 19.4. 31P {1H} NMR (162 MHz, CDCl3) δ 142.7, 142.1, 141.9, 141.5.
HRMS (ESI-QTOF) m/z: [M + H]+ calcd for C49H60N6O6P+, 859.4306; found 859.4292.
For 6c, forty-one hundredths of the crude product (2.50 g out of 6.11 g) was purified via silica gel column chromatography (NH-silica gel) using toluene–EtOAc–tBuOH (99:
1, v/v, containing 0.5% triethylamine) as an eluent to afford 6c as a colorless foam (0.80 g, 0.96 mmol, 39%).
1H NMR (400 MHz, CDCl3) δ 7.92, 7.92, 7.92, 7.92 (d, d, d, d, J = 7.3 Hz, 1H, H-6, mixtures of diastereomers), 7.43–7.17 (m, 14H, Ar), 6.84–6.77 (m, 4H, Ar), 6.33–6.28 (m, 1H, H-1′), 5.51 (qd, J = 7.3, 2.4 Hz, 1H, (5-position of oxazaphospholidine), 5.42–5.34 (m, 1H, H-5, diastereomers), 4.90–4.81 (m, 1H, H-3′), 4.07–4.05 (m, H-4′), 3.77, 3.73, 3.71 (s, s, s, 6H, OC3 × 2, diastereomers), 3.50–3.36 (m, 3H, H-5′, 5′′, 4-position of oxazaphospholidine), 3.09–2.84 (m, 3H, 4-position of oxazaphospholidine, NC
2), 2.60–2.53 (m, 1H, H-2′), 2.33–2.21 (m, 1H, H-2′′), 1.58–1.02 (m, 10H, C
2 × 4, C
× 2), 0.88–0.80 (m, 9H, C
3 × 3). 13C {1H} NMR (101 MHz, CDCl3) δ 165.6, 158.5, 158.5, 158.5, 155.8, 155.7, 144.5, 144.4, 141.3, 141.2, 140.7 (d, 3JPC = 8.7 Hz), 140.6 (d, 3JPC = 9.6 Hz), 140.5 (d, 3JPC = 9.6 Hz), 140.4 (d, 3JPC = 9.6 Hz), 135.5, 135.4, 135.4, 130.1, 130.1, 130.0, 128.4, 128.3, 128.1, 127.9, 126.9, 126.9, 125.8, 125.8, 113.2, 94.0, 93.8, 86.7, 85.7, 85.2, 85.1, 85.0, 81.3 (d, 2JPC = 9.6 Hz), 81.2 (d, 2JPC = 9.6 Hz), 81.1 (d, 2JPC = 9.6 Hz), 81.0 (d, 2JPC = 9.6 Hz), 71.3 (d, 2JPC = 17.3 Hz), 71.2 (d, 2JPC = 18.3 Hz), 71.0, 70.9, 62.1, 61.9, 61.9, 55.2, 55.1, 54.6 (d, 2JPC = 3.9 Hz), 54.5 (d, 2JPC = 4.8 Hz), 54.3 (d, 2JPC = 4.8 Hz), 54.2 (d, 2JPC = 4.8 Hz), 43.6 (d, 2JPC = 22.2 Hz), 43.5 (d, 2JPC = 20.2 Hz), 43.1 (d, 2JPC = 20.2 Hz), 43.1 (d, 2JPC = 19.3 Hz), 39.2, 39.1, 37.3, 37.0, 37.0, 36.7, 36.6, 36.6, 36.4, 36.3, 36.3, 30.5, 30.4, 30.3, 30.3, 27.9, 24.6, 24.6, 22.7, 22.6, 19.7, 19.6, 19.5, 19.4. 31P {1H} NMR (162 MHz, CDCl3) δ 144.6, 144.0, 142.1, 141.6.
HRMS (ESI-QTOF) m/z: [M + H]+ calcd for C48H60N4O7P+, 835.4194; found 835.4200.
All the crude product obtained in the synthesis of 6i was purified via silica gel column chromatography (NH-silica gel) using CHCl3–tBuOH (100:
0–89
:
11, v/v, containing 0.5% triethylamine) as an eluent to afford 6i as a colorless foam (0.30 g, 0.41 mmol, 27%).
1H NMR (400 MHz, CDCl3) δ 8.04, 8.02 (d, d, J = 7.3 Hz, 1H, H-6, mixtures of diastereomers), 7.43–7.17 (m, 14H, Ar), 6.85–6.75 (m, 4H, Ar), 6.31, 6.28 (dd, J = 5.0 Hz, H-1′, 1H, mixtures of diastereomers) 5.49 (q, J = 7.0 Hz, 1H, 5-position of oxazaphospholidine), 5.30, 5.30 (d, J = 7.3 Hz, 1H, H-5, mixtures of diastereomers), 4.93–4.84 (m, 1H, H-3′), 4.07–4.05 (m, 1H, H-4′), 3.79, 3.74, 3.71 (s, s, s, 6H, OC3 × 2, diastereomers), 3.54–3.31 (m, 4H, H-5′, H-5′′ NC
(CH3)2, 4-position of oxazaphospholidine), 2.89–2.82 (m, 1H, 4-position of oxazaphospholidine), 2.65–2.55 (m, 1H, H-2′), 2.38–2.26 (m, 1H, H-2′′), 1.21 (dd, J = 6.4, 4.1 Hz, 3H, NCH(C
3)2), 1.14 (t, J = 6.9 Hz, 3H, NCH(C
3)2). 13C {1H} NMR (101 MHz, CDCl3) δ 165.6, 165.5, 158.6, 158.5, 158.5, 155.8, 155.7, 144.5, 144.4, 141.4, 141.3, 140.5, 140.5, 140.3, 140.2, 135.5, 135.4, 135.4, 130.1, 130.0, 128.4, 128.2, 128.2, 128.0, 127.9, 127.9, 127.0, 126.9, 125.9, 113.2, 93.8, 93.7, 86.7, 86.7, 85.8, 85.7, 85.0, 84.9, 80.7 (d, 2JPC = 9.6 Hz), 80.6 (d, 2JPC = 8.7 Hz), 71.1, 71.0, 70.6, 70.4, 61.8, 55.2, 55.2, 51.2 (d, 2JPC = 4.8 Hz), 51.1 (d, 2JPC = 4.8 Hz), 46.5 (d, 2JPC = 9.6 Hz), 46.3 (d, 2JPC = 9.6 Hz), 41.3, 41.2, 41.0, 22.8 (d, 2JPC = 8.7 Hz), 22.7 (d, 2JPC = 8.7 Hz), 22.6 (d, 2JPC = 6.7 Hz), 22.5 (d, 2JPC = 6.7 Hz). 31P {1H} NMR (162 MHz, CDCl3) δ 143.8, 141.6.
HRMS (ESI-QTOF) m/z: [M + H]+ calcd for C41H46N4O7P+, 737.3099; found 737.3100.
In the case of 6g, all the crude product (4.2 g) was purified via silica gel column chromatography (NH-silica gel) using CHCl3–tBuOH (100:
0–93
:
7, v/v, containing 0.5% triethylamine) as an eluent to afford 6g as a colorless foam (1.59 g) containing 9% oxide and 1% hydrolysate. Afterward, the obtained foam (0.82 g out of 1.59 g) was purified via RP-HPLC (ODS column) using CH3CN–CHCl3 (85
:
15, v/v) as an eluent to afford 6g as a colorless foam (0.61 g, 0.70 mmol, 30%).
1H NMR (400 MHz, CDCl3) δ 7.66 (s, 1H, H-8), 7.43–7.15 (m, 14H, Ar), 6.81–6.75 (m, 4H, Ar), 6.27–6.23 (m, 1H, H-1′), 6.2–6.1 (br, 2H, N2), 5.57–5.54 (m, 1H, 5-position of oxazaphospholidine), 5.02–4.95 (m, 1H, H-3′), 4.21 (q, J = 3.5 Hz, 1H, H-4′), 3.74, 3.73, 3.71 (s, s, s, 6H, OC
3 × 2, diastereomers), 3.55–3.31 (m, 3H, H-5′, 5′′, 4-position of oxazaphospholidine), 3.07–2.98 (m, 2H, NC
2), 2.96–2.89 (m, 1H, 4-position of oxazaphospholidine), 2.86–2.77 (m, 1H, H-2′), 2.52–2.45 (m, 1H, H-2′′), 1.61–1.08 (m, 10H, C
2 × 4, C
× 2), 0.88–0.80 (m, 9H, C
3 × 3). 13C {1H} NMR (101 MHz, CDCl3) δ 159.2, 158.5, 158.4, 153.6, 151.5, 144.5, 144.5, 140.6, 140.5, 135.6, 135.6, 130.1, 128.7, 128.4, 128.3, 128.2, 128.0, 127.9, 127.8, 126.9, 126.9, 126.7, 125.8, 125.8, 117.6, 113.1, 86.4, 85.8 (d, 3JPC = 3.9 Hz), 85.6, 83.9, 81.4, 81.3 (d, 2JPC = 10.6 Hz), 73.0 (d, 2JPC = 12.5 Hz), 63.2, 55.2, 54.8, 54.5 (d, 2JPC = 5.8 Hz), 54.5 (d, 2JPC = 4.8 Hz), 43.7 (d, 2JPC = 22.2 Hz), 43.3 (d, 2JPC = 20.2 Hz), 43.3 (d, 2JPC = 20.2 Hz), 39.6, 39.4, 39.2, 37.3, 37.1, 37.0, 36.8, 36.7, 36.6, 36.5, 36.4, 36.3, 30.7, 30.5, 30.5, 30.3, 27.9, 24.7, 22.7, 22.6, 22.6, 19.6, 19.5, 19.4, 19.4. 31P {1H} NMR (162 MHz, CDCl3) δ 142.8, 142.3, 142.2, 141.8.
HRMS (ESI-QTOF) m/z: [M + H]+ calcd for C49H60N6O7P+, 875.4256; found 875.4256.
All the crude product (2.32 g) obtained in the synthesis of 6t was purified via silica gel column chromatography (NH-silica gel) using toluene–EtOAc (10:
0–8
:
2, v/v, containing 0.5% triethylamine) as an eluent to afford 6t as a colorless foam (1.02 g, 1.20 mmol, 55%).
1H NMR (400 MHz, CDCl3) δ 8.7–8.3 (br, 1H, N-3), 7.63–7.61 (m, 1H, H-6), 7.42–7.19 (m, 14H, Ar), 6.85–6.79 (m, 4H, Ar), 6. 42 (dd, J = 7.5, 6.2 Hz, 1H, H-1′), 5.51–5.45 (m, 1H, 5-position of oxazaphospholidine), 4.92–4.86 (m, 1H, H-3′), 4.11–4.07 (m, 1H, H-4′), 3.77, 3.75, 3.74 (s, s, s, 6H, OC
3 × 2, diastereomers), 3.53–3.33 (m, 3H, H-5′, 5′′, 4-position of oxazaphospholidine), 3.07–2.95 (m, 2H, NC
2), 2.92–2.83 (m, 1H, 4-position of oxazaphospholidine), 2.47–2.29 (m, 2H, H-2′, 2′′), 1.60–1.01 (m, 13H, C
2 × 4, C
× 2, thymine-5-C
3), 0.88–0.80 (m, 9H, C
3 × 3). 13C {1H} NMR (101 MHz, CDCl3) δ 163.6, 158.7, 150.3, 144.3, 144.2, 140.4, 135.6, 135.3, 135.3, 130.1, 130.1, 128.5, 128.2, 128.0, 128.0, 127.2, 127.1, 125.9, 113.2, 111.2, 86.9, 85.8 (d, 3JPC = 4.8 Hz), 85.7, 84.6, 81.3 (d, 2JPC = 9.6 Hz), 81.3 (d, 2JPC = 10.1 Hz), 72.9 (d, 2JPC = 15.4 Hz), 72.6 (d, 2JPC = 13.5 Hz), 63.1, 63.0, 54.7 (d, 2JPC = 4.8 Hz), 54.6 (d, 2JPC = 4.8 Hz), 54.4 (d, 2JPC = 4.8 Hz), 54.3 (d, 2JPC = 5.8 Hz), 43.6 (d, 2JPC = 21.2 Hz), 43.3 (d, 2JPC = 20.2 Hz), 40.5, 40.3, 39.2, 37.3, 37.1, 37.0, 36.7, 36.4, 30.5, 30.4, 30.4, 30.4, 27.9, 24.6, 22.7, 22.6, 19.6, 19.5, 19.4, 11.7, 11.7. 31P {1H} NMR (162 MHz, CDCl3) δ 143.9, 143.4, 142.5, 142.1.
HRMS (ESI-QTOF) m/z: [M + H]+ calcd for C49H61N3O8P+, 850.4191; found 850.4203.
For 6l, ninety-five hundredths of the crude product (2.95 g out of 3.10 g) was purified via silica gel column chromatography (NH-silica gel) using toluene–EtOAc (10:
0–8
:
2, v/v, containing 0.5% triethylamine) as an eluent to afford 6l as a colorless foam (0.82 g, 0.93 mmol, 32%).
1H NMR (400 MHz, CDCl3) δ 9.1–8.7 (br, 1H, N-3), 7.74–7.73 (m, 1H, H-6), 7.48–7.45 (m, 2H, Ar), 7.37–7.17 (m, 12H, Ar), 6.85–6.82 (m, 2H, Ar), 6.78–6.73 (m, 2H, Ar), 5.66 (d, J = 9.6 Hz, 1H, H-1′), 5.54 (t, J = 7.3 Hz, 0.5 H, 5-position of oxazaphospholidine), 5.40 (t, J = 7.3 Hz, 0.5 H, 5-position of oxazaphospholidine), 4.61–4.58 (m, 1H, H-3′), 4.53, 4.47 (s, s, 1H, H-2′, diastereomers), 3.86–3.68 (m, 8H, OC
3 × 2, LNA–C
2), 3.61–3.49 (m, 1.5H, H-5′, 5′′), 3.41–3.38 (m, 1.5H, H-5′′, 4-position of oxazaphospholidine), 3.12–2.79 (m, 3H, 4-position of oxazaphospholidine, NC
2), 1.59–1.00 (m, 13H, C
2 × 4, C
× 2, thymine-5-C
3), 0.89–0.73 (m, 9H, C
3 × 3). 13C {1H} NMR (101 MHz, CDCl3) δ 163.9, 163.8, 158.7, 158.6, 158.5, 149.8, 149.7, 144.4, 144.1, 140.5 (d, 3JPC = 2.9 Hz), 140.4 (d, 3JPC = 2.9 Hz), 140.1 (d, 3JPC = 2.9 Hz), 139.9 (d, 3JPC = 2.9 Hz), 135.4, 135.3, 135.2, 134.6, 134.5, 130.2, 130.1, 128.5, 128.4, 128.3, 128.2, 128.0, 127.9, 127.1, 127.0, 126.8, 125.9, 125.9, 125.7, 113.2, 113.2, 113.2, 113.1, 110.5, 110.5, 88.0, 87.9 (d, 3JPC = 2.9 Hz), 87.2, 86.8, 86.7, 81.7 (d, 2JPC = 9.6 Hz), 81.6 (d, 2JPC = 10.6 Hz), 81.2 (d, 2JPC = 9.6 Hz), 81.2 (d, 2JPC = 9.6 Hz), 78.9, 78.8, 78.8, 78.7, 71.9, 70.8, 70.7, 69.9, 69.8, 69.8, 69.7, 58.0, 57.8, 55.1, 55.1, 54.3 (d, 2JPC = 5.8 Hz), 54.2 (d, 2JPC = 3.9 Hz), 53.9 (d, 2JPC = 4.8 Hz), 53.9 (d, 2JPC = 4.8 Hz), 43.3 (d, 2JPC = 19.3 Hz), 43.1 (d, 2JPC = 21.1 Hz), 42.9 (d, 2JPC = 19.3 Hz), 42.8 (d, 2JPC = 20.3 Hz), 39.1, 37.4, 37.3, 37.1, 37.0, 36.6, 36.5, 36.4, 36.3, 36.3, 36.2, 30.4, 30.3, 30.2, 27.9, 24.6, 24.6, 22.7, 22.6, 22.5, 19.5, 19.4, 19.3, 12.4, 12.3. 31P {1H} NMR (162 MHz, CDCl3) δ 145.3, 144.9, 142.3, 141.7.
HRMS (ESI-QTOF) m/z: [M + H]+ calcd for C50H61N3O9P+, 878.4140; found 878.4141.
The cycles of detritylation, condensation, and oxidation were repeated. After extending the chain length, the HCP was treated with a 25% NH3 aqueous solution–EtOH (3:
1, v/v, 5 mL) at rt for 17 h, filtered, and washed with CH3CN. The filtrate and the washings were combined and concentrated under reduced pressure, and the obtained residue was analyzed via RP-UPLC, which was performed with a linear gradient of 5%–25% MeOH for 10 min in 0.4 M 1,1,1,3,3,3-hexafluoro-2-propanol and 16 mM triethylamine at 50 °C. The purification was conducted with four-fifths of the crude mixture, and the quantity of purified 11 was estimated by measuring the UV absorption at 260 nm. Isolated yield: 14% (11, 57 nmol).
11: HRMS (ESI-QTOF) m/z: [M − 4H]4− calcd for C117H143N45O70P114−, 727.9238; found 727.9209.
1H NMR (500 MHz, D2O) δ 8.19–7.41 (m, 15H, nucleobase), 6.20–5.89 (m, 15H, H-1′, nucleobase), 4.98–3.61 (m, 48H, H-3′, H-4′, H-5′), 3.22–3.18 (q, 66H, TEA), 2.69–2.63 (m, 12H, H-2′), 2.35–2.11 (m, 12H, H-2′), 1.72–1.67 (s, s, 9H, nucleobase), 1.29–1.26 (q, 99H, TEA). 31P {1H} NMR (201 MHz, D2O) −0.48 to −0.61.
The resultant phosphite was boronated using a 1.0 M solution of BH3·THF (50 μL, 50 μmol) and dry THF (950 μL), and the reaction vessel was shaken for 2 min. Afterward, the HCP was washed with dry THF (3 × 1 mL) and dry CH2Cl2 (3 × 1 mL) and the detritylation was performed using 3% DCA in dry CH2Cl2–Et3SiH (1:
1, v/v) (4 × 5 s and 1 × 40 s, 1 mL each). After washing the HCP with dry CH2Cl2 (3 × 1 mL) and CH3CN (3 × 1 mL) and drying in vacuo for 5 min, DMAP (10 mg, 82 μmol), dry 2,6-lutidine (450 μL), and Ac2O (50 μL, 529 μmol) were sequentially added, and the mixture was shaken for 1 min. Subsequently, the HCP was washed with dry CH2Cl2 (3 × 1 mL) and dry CH3CN (3 × 1 mL) and dried in vacuo for 5 min. Dry CH3CN (450 μL) and DBU (50 μL, 335 μmol) were added, and the reaction vessel was shaken for 1 h. The HCP was washed with dry CH3CN (6 × 1 mL), treated with a 25% NH3 aqueous solution–EtOH (3
:
1, v/v, 5 mL) at rt for 17 h (or at rt for 3 h and then 50 °C for 17 h for the synthesis of dAPBT), filtered, and washed with CH3CN. The filtrate and the washings were combined and concentrated under reduced pressure, and the obtained residue was analyzed via RP-HPLC with a linear gradient of 0%–20% CH3CN for 60 min in a 0.1 M TEAA buffer (pH 7.0).
16: HRMS (ESI-QTOF) m/z: [M − 2H]2− calcd for C39H57B3N15O19P32−, 582.6729; found 582.6742.
17: HRMS (ESI-QTOF) m/z: [M − 2H]2− calcd for C39H59B2N15O20P32−, 583.6540; found 583.6559.
The residue obtained in the synthesis of dodecamer 18 was analyzed via RP-HPLC using a linear gradient of 5%–40% MeOH for 20 min in 0.4 M 1,1,1,3,3,3-hexafluoro-2-propanol and 8 mM triethylamine at 60 °C. The purification was conducted with one-twentieth of the crude mixture, and the quantity of purified 18 was estimated by measuring the UV absorption at 260 nm. Isolated yield: 3% (18, 0.8 nmol).
18: HRMS (ESI-QTOF) m/z: [M − 4H]4− calcd for C117H6B2 N45O64P114−, 906.9642; found 906.9630.
Footnote |
† Electronic supplementary information (ESI) available: HPLC profiles, copies of 1H, 13C, 31P NMR, COSY, HMQC and HMBC spectra. See DOI: https://doi.org/10.1039/d3ob01255g |
This journal is © The Royal Society of Chemistry 2023 |